The Schroder UK Public Private Trust could finally see a positive re-rating, having been "left behind" despite a rally in funds investing heavily into the Covid-19 tech and healthcare boom, according to analysts at Stifel.
Investors in the trust, formerly Woodford Patient Capital, have had a rough ride since the company floated on the stockmarket. Shares have lost 70% on their IPO price and 75% since their 119p peak five years ago, having become embroiled in the liquidity crisis at the ill-fated Woodford Investment Management. Schroders took over the trust in December 2019, with fund buyers welcoming the move. Managers Ben Wicks and Tim Creed have been quick to outline their intentions as they look to turn the vehicle's fortunes around. Despite that, the discount on SUPP has only recently started to nar...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
